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Background: There is concern about the increasing rates of loss to follow-up (LTFU) among pre-antiretroviral
therapy (pre-ART) patients in Ethiopia. Little information is available regarding the time when pre-ART patients
are lost to follow-up in the country. This study assessed the time when LTFU occurs as well as the associated
factors among adults enrolled in pre-ART care in an Ethiopian rural hospital.
Methods: Data of all adult pre-ART patients enrolled at the Sheka Zonal Hospital between 2010 and 2013 were reviewed.
Patients were considered lost to follow-up if they failed to keep scheduled appointments for more than 90 days. The
Cox proportional hazards regression model was used to assess factors associated with time until LTFU. The Kaplan-Meier
survival table was used to compare the LTFU experiences of patients, segregated by significant predictors.
Results: A total of 626 pre-ART patients were followed for 319.92 person-years of observation (PYOs) from enrolment to
pre-ART outcomes, with an overall LTFU rate of 55.8 per 100 PYOs. A total of 178 (28.4%) pre-ART patients were lost to
follow-up, 93% of which occurred within the first six months. The median follow-up time was 6.13 months. The independent
predictors included: not having been started on co-trimoxazole prophylaxis (adjusted hazard ratio [AHR] = 1.77, 95%
confidence interval [CI], 1.12–2.79), a baseline CD4 count of or above 350 cells/mm3 (AHR = 1.87, 95%CI, 1.02–3.45), and
an undisclosed HIV status (AHR = 3.04, 95%CI, 2.07–4.45).
Conclusion: A significant proportion of pre-ART patients is lost to follow-up. Not having been started on
co-trimoxazole prophylaxis, presenting to care with a baseline CD4 cell count ≥350 cells/mm3, and an undisclosed HIV
status were significant predictors of LTFU among pre-ART patients. Thus, close monitoring and tracking of patients during
this period is highly recommended. Those patients with identified risk factors deserve special attention.
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article, unless otherwise stated.antiretroviral therapy (ART) [1,2]. More than two-thirds
of the global cases are located in Sub-Saharan Africa
(SSA) [2-5]. Not all patients who present at an earlier
stage of their illness are eligible for ART, and even if
they are eligible, prompt initiation of treatment will de-
pend on several factors including availability of medi-
cines and trained health workers [3,6,7]. Eligible patients
are also hindered from accessing heath care and initiat-
ing treatment due to factors such as distance to health-
care facility, social stigma, being in a less advanceded Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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literacy [2,4,6,8-11]. It is therefore likely that in settings
with a high disease burden and limited resources, some
patients will default from care before they are started on
ART [3,4]. A review of literature on patient retention in
SSA showed that less than one-third of patients remain
continuously in care between the time they test HIV-
positive and start ART [12].
Loss to follow-up [LTFU) among patients enrolled into
HIV care is a persistent challenge in SSA. Although
LTFU among pre-ART patients poses challenges in
Ethiopian ART hospitals [3,6,12-14], it has only recently
began to be recognized in literature [12]. High pre-ART
patient loss is a signal of poor uptake of interventions.
Historically, strategies to address patient LTFU have fo-
cused on the ART period, with greater attention and
resource prioritization given to this, however, LTFU among
pre-ART patients has been given less attention [15-19].
The facility-based annual report of HIV progress at
the Sheka Zonal Hospital indicated that a significant
number of patients who tested positive for HIV failed to
start pre-ART care and those linked to care were lost
before ART initiation [20]. A better understanding of
the time when patients are lost to follow-up and asso-
ciated risk factors in rural Ethiopia could be helpful
for designing time relevant intervention strategies.
The aim of this study was to assess the time when pa-
tients are lost to follow-up and the associated factors
in a cohort of pre-ART patients at the Sheka Zonal
Hospital, rural Ethiopia.
Methods
Study setting and design
This was a retrospective assessment of patients enrolled
in pre-ART care from 2010 to 2013 at the Sheka Zonal
Hospital, southwest Ethiopia, which is located about
611 km from the capital, Addis Ababa. The estimated
catchment population was 120,000, sub-divided into
19 rural and three urban kebeles, of which seven rural
and three urban were located within 10 km of the hos-
pital, the recommended distance for service accessibil-
ity [20,21]. The institution started providing ART in
2006. Other services including voluntary counseling
and testing (VCT), provider-initiated counseling and
testing (PICT), prevention of mother-to-child trans-
mission (PMTCT), and condom promotion are deliv-
ered integrally. Patients are linked to pre-ART care on
the same day of testing by using both internal and
external modes of patient referral systems. Linked
patients are continuously followed-up on pre-ART
care until they are eligible to start lifelong antiretro-
viral drugs (ARVs). The CD4 measurement of pre-
ART patients is taken on the same day of testing for
HIV and then every six months (on average). Allpatient information is registered and kept confiden-
tially both in hard and electronic formats. Pre-ART
patients are appointed for care and follow-up every
three months as per the national and World Health
Organization (WHO) guidelines, except for those in
clinical urgency and chronic management. Adherence
supporters and case managers collect patient informa-
tion. All patient-related data are coded, entered, and
analyzed by data clerks trained by management sci-
ence for health (MSH) and John Hopikin’s university
(JHU) TSEHAI. Up to the time of data collection,
2,170 patients have been enrolled in pre-ART care
since the service started.
Sample size
All 626 adult HIV positive patients enrolled in pre-ART
care at the Sheka Zonal Hospital from September 1, 2010
to August 31, 2013 were included in the study.
Variables
In this study, the baseline explanatory variables were
age, sex, pregnancy status, religion, educational status,
marital status, number of children, dependent children
in the household, place of residence, occupation, disclos-
ure of HIV status, number of CD4 cells count, WHO
clinical stage, provision of co-trimoxazole prophylaxis
therapy (CPT), opportunistic infections, TB status, BMI,
baseline functional status of the patient, availability of
ART clinic in the catchment area (<10 km), and mode of
patient referral system. The major pre-ART outcome
was time until LTFU, defined as the time from the date
of enrolment up to 90 days after the last scheduled ap-
pointment [16,22]. Those who came back after 90 days
of the last scheduled appointment were treated as LTFU
cases. On the other hand, those who were active on
follow-up, were transferred to other facilities, or initiated
treatment at the end of the observation period were
reported as censored cases.
Data were extracted both from the electronic database
and standard registries using a checklist developed from
the WHO and Ethiopian national treatment guidelines
for pre-ART care [13,23].
Data processing, analysis, and interpretation
Data coding, entry, and cleaning was performed using
EpiData version 3.1 and analysis was done using SPSS
version 16.0. To investigate predictors of timing until
LTFU, two strategies were used. First, explanatory vari-
ables were entered into separate bivariate Cox regression
proportional hazards models. Second, all variables from
the bivariate models with p-value ≤0.25 were included in
a final multivariable Cox regression model. Associations
were examined at a p <0.05 significance level.
Table 1 Baseline socio-demographic characteristics of
adult pre-ART patients enrolled in pre-ART care at the
Sheka Zonal Hospital, Sheka Zone, southwest Ethiopia,








15–24 58 (32.6) 87 (22.0)
25–34 80 (44.9) 190 (48.1)
35–44 30 (16.9) 84 (21.3)
44+ 10 (5.6) 34 (8.6)
Sex
Male 67 (37.6) 158 (40.0)
Female 111 (62.4) 237 (60.0)
Occupation
Employed 40 (22.5) 71 (18.0)
Unemployed 67 (37.6) 175 (44.3)
Merchant 23 (12.9) 76 (19.2)
Other 48 (26.9) 73 (18.5)
Educational status
No education 18 (10.1) 72 (18.2)
Primary 68 (38.2) 160 (40.5)
Secondary 51 (28.7) 87 (22.0)
Tertiary and
above
41 (23.0) 76 (19.2)
Religion
Orthodox 121 (68.0) 273 (69.1)
Muslim 30 (16.9) 57 (14.4)
Protestant 23 (12.9) 55 (13.9)
Other 4 (2.2) 10 (2.5)
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ber of patients lost to follow-up during a particular
period of time divided by the total number of years of
follow-up during this period. The proportional hazard
assumption was assessed by performing log-log survival
curves based on Schoenfeld residuals. Variables with in-
complete data were entered as “missing”; the rate of
missing data for all variables was below 2.7%.
The Kaplan-Meier survival table was used to compare
LTFU experiences of pre-ART patients segregated by
significant predictor variables at enrolment. Incidence
density was calculated for LTFU cases using person-
years of contribution to the cohort.
Ethical statement
The study protocol was approved by the Institutional
Review Board of Jimma University, Ethiopia.
Results
Between 2010 and 2013, a total of 659 patients were
enrolled in pre-ART care. Of these, 626 were eligible for
this study based on the inclusion criteria.
Socio-demographic characteristics of the patients
The mean age of participants was 30.6 (SD, 8.7) years,
59.4% were females, and 4.4% of the females were
pregnant. Of the total participants, 58.0% were married,
34.4% had dependent children below 15 years of age,
39.5% had primary level education, and 67.3% were
Orthodox Christians. More than half (50.8%) were from
rural communities and 34.9% were of the Amhara ethni-
city. The selected socio-demographic characteristics of
the study participants, by pre-ART outcome, are pre-
sented in Table 1.
Baseline characteristics of the patients
Of the 626 patients enrolled in pre-ART care, 374
(59.7%) were early stage presenters and 413 (66%) were
linked to care with a baseline CD4 count ≥350 cells/ml.
The baseline mean CD4 cell counts were 469.9 (SD,
323.2) cells/mm3 and 879.7 (SD, 349.5) cells/mm3for
retained and LTFU patients, respectively.
Of the 79.2% of patients who had experienced at least
one type of opportunistic infection during presentation
to care, 341 (54.5%) had been treated with CPT.
Of the total participants, 227 (37.2%) were under-
weight (BMI ≤18.5), 377 (61.8%) were of normal weight
(BMI = 18.5–24.9), and 6 (1.0%) were overweight (BMI
≥25). Regarding tuberculosis (TB) screening, 625 (99.8%)
were screened for TB, of which 106 (17%) were positive.
In terms of the baseline functional status of the cohort
during presentation to care, 578 (92.6%) were at working
conditions and the rest (4%) and (3.4%) were at ambula-
tory and bedridden conditions, respectively.Service availability, mode of referral, and disclosure of
HIV status
Of the total participants, 424 (67.9%) were in the catchment
area of the zonal hospital and 528 (85.2%) were linked to
pre-ART care using the internal mode referral. Regarding
disclosure of HIV status, 368 (59%) disclosed their HIV sta-
tus, of which 332 (90.2%) did so to their family members.
The rest of the patients (41%) had not disclosed the status
to anyone.Outcomes during follow-up period
Patients were followed up with pre-ART care from
2010 to 2013 for 319.92 person-years of observation
(PYOs). At the end of the observation period, of the
patients who were enrolled in pre-ART care, 178
(28.4%) were lost to follow-up, 20 (3.2%) were trans-
ferred to another facility, 268 (42.8%) had initiated
treatment, 33 (5.3%) had died, and 127 (20.3%) were
found to be active in pre-ART care. The overall LTFU
rate was 55.8 per 100 PYOs. Among those patients lost
to follow-up, 111 (62.4%) were female. The number of
LTFU cases among pregnant women in the pre-ART
patient cohort was not reported during the study
period.
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A total of 626 patients were followed for a median of
6.13 (IQR, 4.57–13.23) months in pre-ART outcomes.
The minimum follow-up time was three days and the
maximum was 1,080 days (around 36 months). After a
six-month period, 166 (93.26%) patients were lost to
follow-up and this number grew to 171 (96.07%) at the
end of one year, starting from the period of enrolment
(see Table 2).
The mean estimate of LTFU time for patients who
started CPT at pre-ART care during enrolment was 9.88
(95% CI, 9.5–8.3) months, whereas for patients who
were not started on CPT, it was 5.55 (95% CI, 4.9–6.2)
months. The difference in time between the two categor-
ies of patients was statistically significant (p <0.001).
Similarly, the mean estimate of time until LTFU for
patients who disclosed their HIV status to their family
members was 9.8 (95% CI, 9.4–10.3) months, whereas
for patients who did not disclose their HIV status to any-
one when enrolling into care was 5.0 (95% CI, 4.3–5.7)
months. The observed difference was statistically signifi-
cant (p <0.001).
At enrolment, the cumulative proportions of patients
retained were higher among patients who started CPT,
disclosed their HIV status to their family members, and
who had a baseline CD4 ≥ 350 (see Table 3).Factors associated with time to LTFU
During the bivariate analysis of factors associated
with time to LTFU, six explanatory variables with
p-values <0.25 were selected for the multivariate Cox
regression model. These included provision of CPT at
enrolment, service availability, CD4 cell count, oppor-
tunistic infections, WHO clinical stage, and HIV status
disclosure. Three predictor variables, CPT at enrol-
ment, baseline CD4 count, and HIV status disclosure,
were found to be independent predictors of time until
LTFU (see Table 4).Table 2 Estimated number of LTFU cases among pre-ART
patients at the end of observation periods spanning
3, 6, 12, 24, and 36 months at Sheka Zonal Hospital,
southwest Ethiopia, between 2010 and 2013
Observation period
(in months) LTFU cases Cumulative loss
Cumulative
loss in %
At 3 months 136 136 76.40
At 6 months 30 166 93.26
At 12 months 5 171 96.06
At 24 months 7 178 100.00
At 36 months 0 178 100.00
Total 178Discussion
Currently, the need to focus on retaining patients start-
ing pre-ART care and not just patients being initiated on
ART is being emphasized [5,6,18,24,25]. This study ex-
amined LTFU among pre-ART patients and associated
factors in rural Ethiopia. In this study, the rate of LTFU
in pre-ART care was high and was significantly associ-
ated with not having been started on CPT, presenting to
care with a baseline CD4 ≥ 350 cells/mm3, and an undis-
closed HIV status.
In this study, the overall rate of LTFU in pre-ART care
was 28.4%. Compared to findings from different settings,
this percentage is higher [18,26,27]. The differences
could be due to variations in study design, definitions,
and patient follow-ups. Unlike our study, which defined
pre-ART patients as all newly enrolled HIV patients re-
gardless of their clinical stage and CD4 count, studies
conducted in other settings [17,25,28] focused on pre-
ART patients with low CD4 cell counts and an advanced
disease stage.
The incidence of pre-ART LTFU was highest in the
first year of study. Approximately 96% of LTFU cases
occurred in the first year and all LTFU occurred at the
end of the two-year observation period. This is higher by
nearly 10% when compared to findings from Nigeria that
showed that 88.0% of LTFU cases occurred in the first
year and all deaths occurred in the first six months of
pre-ART care [12]. This variation may be due to poor
monitoring and tracking of defaulting patients observed
during early periods of pre-ART care [6,12,16].
Over three-quarters of pre-ART patients (83.8%) who
did not start CPT at enrolment were lost to follow-up,
compared to about 16% of those who did. The time until
LTFU for patients who were started on CPT at pre-ART
care enrolment was nearly two-fold higher than those
who were not started on CPT. Furthermore, the patients
on CPT had more than a 30% reduction in risk of LTFU
six months into treatment and an increased retention
time after adjustment for other explanatory variables
compared to those who did not start CPT at enrolment,
with the difference statistically significant (see Figure 1A).
In a Kenyan study, treatment of ART ineligible patients
with co-trimoxazole improved the 12-month retention
in care from 63% to 84%; this suggests that patients may
have perceived more benefit from CPT. Part of the
underlying reasons for the high rate of LTFU among
pre-ART patients not treated with CPT could be the lack
of means for engaging these patients in care. Such pa-
tients are often not treated with CPT for opportunistic
infections when their CD4 cell counts are high or if
patients are at less advanced disease stages and it is indi-
cated that provision of free medicines or nutrition can
improve visits to the clinic and therefore, the retention
in pre-ART care [6,12,29,30].
Table 3 Comparisons of LTFU experiences among pre-ART patients, by CPT status and HIV status disclosure at
enrolment, Kaplan-Meier survival table
Baseline variable Time in months Status Cumulative proportionsurviving at time T N of cumulative attritions N of remaining cases
CPT provision
Yes
At 3 LTFU 0.93 20 316
At 6 LTFU 0.88 30 102
No
At 3 LTFU 0.61 111 117
At 6 LTFU 0.49 136 108
Disclosure of HIV status
To family
At 3 LTFU 0.93 23 309
At 6 LTFU 0.89 29 119
Not at all
At 3 LTFU 0.59 105 151
At 6 LTFU 0.46 125 74
CPT: co-trimoxazole prophylaxis therapy.
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for LTFU among pre-ART patients in Durban, South Africa
[31] and in Uganda [32]. Findings from these studies
contradict our study finding where patients with higher
CD4 cell counts were at an increased risk of LTFU (see
Figure 1B). This could be due to methodological differences
with respect to operational definitions and also differences
between the study settings [31-33]. On the other hand, this
study’s finding regarding the association between a less
advanced disease stage and pre-ART LTFU was consistentTable 4 Cox regression analysis for independent predictors o
southwest Ethiopia, from 2010 to 2013
Variables Crude HR 95% CI
CPT at enrolment
Provided 1.0




Disclosure of HIV status
To family members
To other relatives 2.43 1.47–2.66





Within <10 km 1.0




**Reference category, CPT: co-trimoxazole prophylaxis therapy, AHR: adjusted hazarwith a study conducted in southern Ethiopia with similar
operational definitions and study settings [6]. This finding
was also supported by a study conducted in South Africa
where the probability of returning to care reduced for
patients with higher CD4 cell counts [34]. Part of the
explanation for the increased risk of pre-ART LTFU among
patients with better immune statuses or less advanced
disease stages could result from patients’ self-assessment of
feeling healthy and might have been more reluctant to be
on pre-ART [9,35,36].f timing until LTFU at the Sheka Zonal Hospital,
P-value AHR 95.0% CI AHR P-value
1.0
0.000 1.77 1.12–2.79 0.015
1.0
0.04 1.87 1.02–3.45 0.044
1.0
0.008 2.0 1.03–3.90 0.044
0.000 3.04 2.07–4.45 0.000
0.038 0.99 0.65–1.53 0.99
1.0
1.0
0.000 1.28 0.93–1.74 0.13
1.0
0.000 1.24 0.89–1.72 0.198
d ratio, CI: confidence interval.
Figure 1 Pre-ART patient LTFU experiences segregated by baseline (A) Cotrimoxazole (CPT) provision (B) baseline CD4 category and (C) HIV disclosure
status among adult pre-ART patients enrolled to pre-ART care at Sheka Zonal Hospital, rural Ethiopia, during 2010–2013.
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significantly associated with time until LTFU among
pre-ART patients. Compared to those patients who dis-
closed their HIV status to their family members, those
who did not disclose it to anyone had a nearly three
times higher risk of LTFU (see Figure 1C). In one study,
disclosure status did not show a significant association
[37] and this could be due to differences in methodo-
logical variations. But, a study in Ethiopia indicated that
HIV positive people experience both discriminatory ex-
clusion and isolation from society, which further dis-
courages disclosure of their HIV status. As a result,
status disclosure and health-seeking behavior could be
negatively affected. Similarly, among interviewed pre-
ART patients from Addis Ababa, 50% had not disclosedtheir HIV status due to fear of rejection from household
members, thus they attiritted from care [37]. Another
systematic review of 34 studies supports the notion that
HIV status disclosure can improve access to HIV/AIDS
care and, therefore, the retention in pre-ART care [38].
Part of the underlying explanation for undisclosed HIV
status can be fear of stigma and rejection from house-
hold members and the community at large [38,39].
Limitations of the study
This study was not without limitations. The number of
lost to follow-up patients might have been overestimated
because patients might have been dying at home without
reporting it. Using data with incomplete information
might have also introduced bias.
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A high rate of LTFU among pre-ART patients was ob-
served, with more than one-third of patients being lost
to follow-up in the first year of pre-ART care. Analysis
of predictor variables indicated that high LTFU rates
were associated with no CPT at enrolment, a baseline
CD4 cell count ≥350 cells/mm3, and not disclosing HIV
status.
Close monitoring and improved tracking of patients is
recommended during the early periods of pre-ART care.
In addition, the preventive intervention should be scaled
up in a manner that all CPT-eligible pre-ART patients
get this intervention promptly. Treatment programs
must make greater efforts to retain patients in care prior
to ART initiation, particularly those who are in good
health at enrollment, so that they can start ART as soon
as they become eligible. Patients should also endeavor to
avail services in their catchment area and increase timely
communication with family members.
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